GCG and Parkinson disease: Other clinical trials testing GLP-1 type drugs in PD patients are currently ongoing, testing the drugs semaglutide (NCT03659682), lixisenatide (NCT03439943), NLY01 (NCT04154072), or PT320 (NCT04269642) in PD patients, with additional phase 2 (NCT04305002) and phase 3 (NCT04232969) trial testing exenatide in PD patients, highlighting the growing interest and demand for discovery and development of GLP-1R agonists.